Literature DB >> 19343478

Natural history of transfusion-independent non-severe aplastic anemia in children.

Nobuhiro Nishio1, Hiroshi Yagasaki1, Yoshiyuki Takahashi1, Hideki Muramatsu1, Asahito Hama1, Nao Yoshida1, Kazuko Kudo1,2, Seiji Kojima3.   

Abstract

Although the known clinical courses of non-severe aplastic anemia (NSAA) in children comprise spontaneous resolution, persistent NSAA, or progression to severe aplastic anemia (SAA), only a few published reports have indicated the outcome of transfusion-independent NSAA. We retrospectively evaluated the incidence and time of progression from transfusion-independent to transfusion-dependent NSAA or SAA. We reviewed the records of 70 children with acquired AA who were referred to our hospital between 1986 and 2006, and among them we found 22 patients who had transfusion-independent NSAA at diagnosis and were treated with supportive care alone until progression to transfusion-dependent AA. 22 patients were followed up for a median of 86 months (range, 11-198 months). The Kaplan-Meier estimates for progression-free survival were 62 +/- 12 and 22 +/- 13% at 60 and 120 months after diagnosis, respectively. None of the patients treated with supportive care alone improved hematologically. In conclusion, because the incidence of disease progression was high in patients with NSAA, a prospective randomized trial of early intervention with IST or observation alone until disease progression to SAA, followed by IST when the patients become transfusion-dependent is warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19343478     DOI: 10.1007/s12185-009-0302-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.

Authors:  S Kojima; K Horibe; J Inaba; A Yoshimi; Y Takahashi; K Kudo; K Kato; T Matsuyama
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

2.  Guidelines for the diagnosis and management of acquired aplastic anaemia.

Authors:  J C W Marsh; S E Ball; P Darbyshire; E C Gordon-Smith; A J Keidan; A Martin; S R McCann; J Mercieca; D Oscier; A W W Roques; J A L Yin
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

3.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

4.  A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia.

Authors:  B M Camitta; E D Thomas; D G Nathan; R P Gale; K J Kopecky; J M Rappeport; G Santos; E C Gordon-Smith; R Storb
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

5.  Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.

Authors:  Monika Führer; Udo Rampf; Irith Baumann; Andreas Faldum; Charlotte Niemeyer; Gritta Janka-Schaub; Wilhelm Friedrich; Wolfram Ebell; Arndt Borkhardt; Christine Bender-Goetze
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Authors:  N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

7.  Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.

Authors:  S Kojima; S Hibi; Y Kosaka; M Yamamoto; M Tsuchida; H Mugishima; K Sugita; H Yabe; A Ohara; I Tsukimoto
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

8.  Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Elaine M Sloand; Olga Nunez; Carol Boss; Neal S Young
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

9.  Outcome of moderate aplastic anemia in children.

Authors:  Z Khatib; J Wilimas; W Wang
Journal:  Am J Pediatr Hematol Oncol       Date:  1994-02

10.  Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT).

Authors:  A Bacigalupo
Journal:  Haematologica       Date:  1994 Sep-Oct       Impact factor: 9.941

View more
  10 in total

1.  Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

Authors:  Atsushi Narita; Hideki Muramatsu; Yuko Sekiya; Yusuke Okuno; Hirotoshi Sakaguchi; Nobuhiro Nishio; Nao Yoshida; Xinan Wang; Yinyan Xu; Nozomu Kawashima; Sayoko Doisaki; Asahito Hama; Yoshiyuki Takahashi; Kazuko Kudo; Hiroshi Moritake; Masao Kobayashi; Ryoji Kobayashi; Etsuro Ito; Hiromasa Yabe; Shouichi Ohga; Akira Ohara; Seiji Kojima
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

2.  Clinical course of non-severe aplastic anemia in adults.

Authors:  Ji Hyun Kwon; Inho Kim; Yun Gyoo Lee; Youngil Koh; Hayne Cho Park; Eun Young Song; Hyun Kyung Kim; Sung Soo Yoon; Dong Soon Lee; Sung Sup Park; Hee Young Shin; Seonyang Park; Myoung Hee Park; Hyo Seop Ahn; Byoung-Kook Kim
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

Review 3.  Diagnosis and Treatment of Aplastic Anemia.

Authors:  Scott A Peslak; Timothy Olson; Daria V Babushok
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

4.  Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.

Authors:  Hirohito Yamazaki; Kensuke Ohta; Hiroatsu Iida; Kazunori Imada; Naoshi Obara; Yukihiro Tokumine; Yoshiaki Tomiyama; Kensuke Usuki; Kenji Imajo; Koichi Miyamura; Osamu Sasaki; Zhang Fanghong; Toshihiro Hattori; Takeshi Tajima; Akira Matsuda; Shinji Nakao
Journal:  Int J Hematol       Date:  2019-06-10       Impact factor: 2.490

5.  Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children.

Authors:  Yuichi Kodama; Yasuhiro Okamoto; Teruto Hashiguchi; Yuichi Shinkoda; Takuro Nishikawa; Takayuki Tanabe; Yoshifumi Kawano
Journal:  Int J Hematol       Date:  2012-04-22       Impact factor: 2.490

6.  Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.

Authors:  Hongchen Liu; Xiaoli Zheng; Chengtao Zhang; Jiajun Xie; Beibei Gao; Jing Shao; Yan Yang; Hengxiang Wang; Jinsong Yan
Journal:  Front Med       Date:  2021-06-25       Impact factor: 4.592

Review 7.  Acquired aplastic anemia in children.

Authors:  Helge D Hartung; Timothy S Olson; Monica Bessler
Journal:  Pediatr Clin North Am       Date:  2013-10-16       Impact factor: 3.278

8.  The progression risk factors of children with transfusion-independent non-severe aplastic anemia.

Authors:  Shuchun Wang; Yumei Chen; Yao Zou; Yizhou Zheng; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2013-01-30       Impact factor: 2.490

9.  Distinctive and common features of moderate aplastic anaemia.

Authors:  Bhumika J Patel; Shimoli V Barot; Teodora Kuzmanovic; Cassandra Kerr; Bartlomiej P Przychodzen; Swapna Thota; Sarah Lee; Saurabh Patel; Tomas Radivoyevitch; Alan Lichtin; Anjali Advani; Matt Kalaycio; Mikkael A Sekeres; Hetty E Carraway; Jaroslaw P Maciejewski
Journal:  Br J Haematol       Date:  2020-01-31       Impact factor: 8.615

10.  Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Limin Liu; Xin Zhao; Miao Miao; Yanming Zhang; Wenjing Jiao; Meiqing Lei; Huifen Zhou; Qingyuan Wang; Yifeng Cai; Liyun Zhao; Xiaohui Shangguan; Zefa Liu; Jinge Xu; Fengkui Zhang; Depei Wu
Journal:  Front Oncol       Date:  2021-09-21       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.